

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Myeloma

Sixth Guideline Development Group (GDG) meeting

16th October 2014

Cancer Research UK Clinical Trials Unit, Birmingham University

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Curly Morris (CM)	Monica Morris (MM)
Guy Pratt (GP)	Nicola Mulholland (NM)
Sam Ahmedzai (SA)	Lesley Roberts (LR)
Alan Chant (ACh)	Hamdi Sati (HS)
Matthew Jenner (MJ)	Matthew Streetly (MS)
Nicola Montacute (NMo)	Jane Woodward (JW)
NCC-C staff	
Angela Bennett (AB)	Angharad Morgan (AM)
Elise Hasler (EH)	Victoria Titshall (VT)
James Hawkins (JH)	
NICE staff	
Katie Perryman-Ford (KPF)	
Apologies	
Andrea Guy (AG)	John Snowden (JS)
John Graham (JG)	Andrew Champion (AC)

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

CM welcomed everyone to the 6th meeting of the Myeloma GDG. Apologies were received from Andrea Guy, John Snowden, John Graham and Andrew Champion.

CM welcomed Tor Titshall who is a project manager covering in Kim's absence.

CM advised the GDG that an expert adviser – Isabel Syndikus would be attending for agenda item 4, to provide her views on this area.

2. Declarations of Interest

The following declarations of interest were declared prior to the meeting:

- for Takeda on ixazomib. This interest was categorised as personal pecuniary, non-specific meaning that GP can participate in discussion of all guideline topics as the ixazomib is not being investigated by the guideline.
- GP declared that he will receive an honorarium for chairing a medical advisory board for Amgen on carfilzomib. This interest was categorised as personal pecuniary, specific meaning that GP must withdraw from discussion of all guideline topics which include carfilzomib as an intervention until October 2015.
- GP declared that he will receive reimbursement of travel and subsistence expenses from the Binding Site Ltd to attend the American Society of Haematology Conference in San Francisco. This interest was categorised as personal pecuniary, non-specific meaning that GP can participate in

discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.

- GP declared that he will receive reimbursement of travel and subsistence expenses from the Binding Site Ltd to attend their meeting in Edinburgh. This interest was categorised as personal pecuniary, non-specific meaning that GP can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.
- GP declared that he will be giving a presentation on the management of myeloma for Sebia UK Ltd in Birmingham. This interest was categorised as personal non-pecuniary, non-specific meaning that GP can participate in discussion of all guideline topics as no payment was received.
- GP declared that he will receive reimbursement of travel and subsistence expenses from Helena Biosciences Europe for giving a talk on international standards for diagnosis and relapse in myeloma in Barcelona. This interest was categorised as personal pecuniary, non-specific meaning that GP can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.
- HS declared that he received reimbursement of travel and subsistence expenses from SHIRE for attending the 19th annual meeting in Milan. This interest was categorised as personal pecuniary, non-specific meaning that HS can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.
- HS declared that he received reimbursement of travel and subsistence expenses from Celgene for attending the European Multiple Myeloma Academy meeting in Vienna. This interest was categorised as personal pecuniary, non-specific meaning that HS can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.
- HS declared that he received reimbursement of travel, subsistence and registration expenses from Bristol-Myers Squibb for attending the American Society of Haematology meeting in San Francisco. This interest was categorised as personal pecuniary, non-specific meaning that HS can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.
- HS declared that he is the local principle investigator for a trial examining ixazomib maintenance therapy post autologous stem cell transplant in newly diagnosed multiple myeloma patients. The trial is sponsored by TAKEDA. This interest was categorised as non-personal pecuniary, non-specific meaning that HS can participate in discussion of all guideline topics as he has no supervisory responsibility on the trial and the guideline is not covering maintenance therapy.
- MM declared that she acts as a reviewer for the myeloma section of the Cancer Research UK patient information website (CancerHelp UK). This review is done every 2 years. MM receives a small payment from CRUK. This interest was categorised as personal pecuniary, non-specific meaning that MM can participate in discussion of all guideline topics as the review is on myeloma in general and it is not funded from the healthcare industry.

No new declarations of interest were declared at the meeting.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GDG discussed the evidence and agreed the recommendations and LETR tables for topics K and L2.

JH discussed the assumed parameters for the health economic model of topic L3.

4. Close of meeting

CM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Tuesday 2nd & Wednesday 3rd December 2014**, starting at 10.30 in the **Board Room, NCC-C offices, Cardiff**.